StockData
Genmab A/S logo

Genmab A/S

GMABNasdaqPharmaceutical PreparationsAlso trades as GNMSF
Financials through fiscal 2025, year ended Dec 31, 2025Score 0/30
$51.35+0.38 (+0.75%)

Close on Nov 19, 2026

Genmab A/S SG&A & Commercial Employees at Period-End (FTEs) by Quarter

Genmab A/S SG&A & Commercial Employees at Period-End (FTEs): 1,163 in Q3 2026, up 38.5% from a year earlier. That is the highest of the 30 quarters on record here.

Latest, Q3 2026
1,163
Period ended Sep 30, 2026
Change on a year earlier
+38.5%
840 in Q3 2025
History
30 quarters
Since Q1 2019
Sources
27
Documents cited below

Where the Q3 2026 figure comes from

“|| Selling, general and administrative employees | 1,163 | 840”

Source: Genmab Form 6-K — Q3 2026 Interim Report (Nine Months Ended Sep 30, 2026) ↗

Consolidated commercialization, medical affairs, field sales, and corporate administrative FTEs (35.9% of total workforce as of Q3 2026).

quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedSG&A & Commercial Employees at Period-End (FTEs)Year on yearSource
Q3 2026Sep 30, 20261,163+38.5%Genmab Form 6-K — Q3 2026 Interim Report (Nine Months Ended Sep 30, 2026) ↗
Q2 2026Jun 30, 20261,063+31.4%Genmab Form 6-K — H1 / Q2 2026 Interim Report (Six Months Ended Jun 30, 2026) ↗
Q1 2026Mar 31, 20261,061+32.5%Genmab Form 6-K — Q1 2026 Interim Report (Three Months Ended Mar 31, 2026) ↗
Q4 2025Dec 31, 2025940+18.1%Genmab Form 20-F — FY2025 Annual Report (Year Ended Dec 31, 2025) ↗
Q3 2025Sep 30, 2025840+7.4%Genmab Form 6-K — Q3 2025 Interim Report (Nine Months Ended Sep 30, 2025) ↗
Q2 2025Jun 30, 2025809+7.6%Genmab Form 6-K — H1 / Q2 2025 Interim Report (Six Months Ended Jun 30, 2025) ↗
Q1 2025Mar 31, 2025801+16.9%Genmab Form 6-K — Q1 2025 Interim Report (Three Months Ended Mar 31, 2025) ↗
Q4 2024Dec 31, 2024796+20.1%Genmab Form 20-F — FY2024 Annual Report (Year Ended Dec 31, 2024) ↗
Q3 2024Sep 30, 2024782+20.7%Genmab Form 6-K — Q3 2024 Interim Report (Nine Months Ended Sep 30, 2024) ↗
Q2 2024Jun 30, 2024752+21.5%Genmab Form 6-K — H1 / Q2 2024 Interim Report (Six Months Ended Jun 30, 2024) ↗
Q1 2024Mar 31, 2024685+23.9%Genmab Form 6-K — Q1 2024 Interim Report (Three Months Ended Mar 31, 2024) ↗
Q4 2023Dec 31, 2023663+42.0%Genmab Form 20-F — FY2023 Annual Report (Year Ended Dec 31, 2023) ↗
Q3 2023Sep 30, 2023648+50.3%Genmab Form 6-K — Q3 2023 Interim Report (Nine Months Ended Sep 30, 2023) ↗
Q2 2023Jun 30, 2023619+56.7%Genmab Form 6-K — H1 / Q2 2023 Interim Report (Six Months Ended Jun 30, 2023) ↗
Q1 2023Mar 31, 2023553+55.8%Genmab Form 6-K — Q1 2023 Interim Report (Three Months Ended Mar 31, 2023) ↗
Q4 2022Dec 31, 2022467+63.9%Genmab Form 20-F — FY2022 Annual Report (Year Ended Dec 31, 2022) ↗

Cite this data

StockData. (2026). Genmab A/S SG&A & Commercial Employees at Period-End (FTEs), quarterly Q1 2019–Q3 2026 [Data set]. Compiled from Genmab A/S SEC filings and investor materials. https://stockdatahq.com/stocks/gmab/kpis/fte-sga

See every metric in the Genmab A/S KPI table. Data updated Nov 11, 2026.

See a number that looks wrong?